Ondansetron is an antiemetic medication commonly prescribed to help prevent and manage nausea and vomiting caused by:

GLP-1 medications

Surgery

Chemotherapy

Radiation therapy

Acute gastrointestinal illness

It works by blocking serotonin (5-HT3) receptors involved in triggering nausea and vomiting.

Yes. Zofran is the well-known brand name for ondansetron. Generic ondansetron contains the same active ingredient and is commonly prescribed in the United States.

Yes. Ondansetron requires a valid prescription in the United States and is not currently available over the counter (OTC).

Yes. Ondansetron is legal in the United States when prescribed by a licensed healthcare provider. It is not classified as a controlled substance.

In many cases, licensed telemedicine providers may prescribe ondansetron after reviewing your medical history and symptoms, depending on state regulations and clinical appropriateness.

Routine blood work is not always required for short-term ondansetron use. However, providers may recommend labs in certain cases, especially for patients with chronic nausea, cardiac conditions, liver disease, or ongoing medication use.

Possible labs may include:

Comprehensive Metabolic Panel (CMP)

Liver function tests

Electrolyte testing (potassium and magnesium)

CBC (Complete Blood Count)

These tests may help identify electrolyte imbalances or other conditions that could increase the risk of side effects.

Yes. Ondansetron may interact with certain medications that affect heart rhythm or serotonin levels. Patients should disclose all prescription medications, supplements, and medical conditions to their provider before use.

In rare cases, ondansetron may affect heart rhythm, including QT prolongation, especially in patients with electrolyte imbalances, existing cardiac conditions, or when combined with certain medications.

Many patients report symptom relief within 30 minutes to 2 hours depending on the dosage form and individual response.

Effects commonly last between 4 to 8 hours, though this may vary depending on dosage, metabolism, and treatment purpose.

Yes. Ondansetron is commonly discussed as supportive therapy for nausea associated with GLP-1 medications such as semaglutide or tirzepatide, although treatment decisions should always be made by a licensed provider.

Some patients may use ondansetron longer term under medical supervision. Providers may monitor electrolyte levels, liver health, medication interactions, and symptom progression depending on treatment duration.

Although widely used, ondansetron remains prescription-only in the United States partly due to concerns involving cardiac rhythm risks, medication interactions, and the importance of evaluating underlying causes of nausea.

Yes. Ondansetron is an FDA-approved prescription medication available in 4 mg and 8 mg tablets. A valid prescription from a licensed provider is required. Available in #7, #14, and #30 counts at the same price per dose for both strengths.

Headache is the most commonly reported side effect. Constipation may occur with regular use given 5-HT3's role in GI motility. Transient elevation in liver enzymes has been reported. QT interval prolongation is a rare but serious cardiac effect and requires monitoring in patients with pre-existing cardiac conditions or on QT-prolonging medications. Dizziness and fatigue occur occasionally.

Not for patients with known hypersensitivity to ondansetron or other 5-HT3 antagonists. Congenital long QT syndrome is a contraindication. Not for concurrent use with apomorphine due to risk of profound hypotension and loss of consciousness. Patients on QT-prolonging medications require ECG monitoring and provider evaluation before use.

Concurrent use with apomorphine is absolutely contraindicated due to severe hypotension risk. QT-prolonging agents including certain antiarrhythmics, antipsychotics, and fluoroquinolones require provider evaluation given additive QT effects. CYP3A4 and CYP1A2 inducers including rifampin and carbamazepine reduce ondansetron plasma levels. Serotonergic agents including SSRIs and SNRIs increase serotonin syndrome risk with concurrent use.

Patients with hepatic impairment require dose reduction as ondansetron clearance is significantly reduced; a maximum of 8 mg per day is recommended in severe hepatic disease. Patients with cardiac arrhythmias, electrolyte abnormalities, or those on QT-prolonging medications require cardiac evaluation before use. Patients with phenylketonuria should note that some formulations contain phenylalanine.